ArticlePediatric dermatology
Successful Treatment of Severe Purpura Fulminans With Anakinra.
Article in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Post-Infectious Purpura Fulminans in a Healthy Child: A Case Report.Case reports in dermatologyArticle
- Successful Treatment of Severe Purpura Fulminans With Anakinra.Pediatric dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpura fulminans (PF) is a rare, often fatal pediatric condition characterized by intravascular thrombosis and hemorrhagic infarction of the skin. A timely diagnosis and treatment are paramount to prevent the involvement of internal organs, causing disseminated intravascular coagulation and gangrene of the extremities. The management of PF requires a comprehensive approach, including the treatment of the underlying infection, anticoagulation, and anti-inflammatory therapy. Herein we present the case of a child with severe PF successfully treated with anakinra, an anti-IL1-receptor monoclonal antibody.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.